Imperial College London


Faculty of MedicineDepartment of Immunology and Inflammation

Professor of Haemato-oncology



+44 (0)20 3313 3237j.apperley




Miss Mandy Sale +44 (0)20 3313 4017




4N3CHammersmith HospitalHammersmith Campus






Cross NCP, Ernst T, Branford S, et al., 2023, European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia, Leukemia, Vol:37, ISSN:0887-6924, Pages:2150-2167

Ortí G, Gras L, Koster L, et al., 2023, Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)., Transplant Cell Ther


Apperley J, Cortes J, Jabbour E, et al., 2023, Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial, CIG MEDIA GROUP, LP, Pages:S339-S339, ISSN:2152-2650

Mauro M, Hochhaus A, Hughes T, et al., 2023, Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study, CIG MEDIA GROUP, LP, Pages:S340-S340, ISSN:2152-2650

Cortes J, Deininger M, Lomaia E, et al., 2023, Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib, CIG MEDIA GROUP, LP, Pages:S338-S338, ISSN:2152-2650

More Publications